SNDX — Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $45.9 million, a 21% increase from the previous quarter.
• Revuforj Revenue: $32 million, up 12% quarter-over-quarter, with a 25% increase in total prescriptions and new patient starts.
• Niktimvo Revenue: $13.9 million, a 27% increase from the prior quarter.
• Cash Position: $456 million in cash and equivalents, providing a strong financial foundation for future growth.

2. Strategic Updates and Business Highlights

• Revuforj: Now FDA-approved for relapsed/refractory NPM1 mutated AML, expanding the addressable patient population from 2,000 to 6,500, representing a $2 billion market opportunity.
• Niktimvo: Strong growth trajectory with annualizing sales nearing $200 million; positive cash flow contributor to Syndax.
• Clinical Development: Enrollment is underway for pivotal trials (EVOLVE-2 for Revuforj and frontline trials for Niktimvo) that could unlock a combined market opportunity exceeding $10 billion.
• ASH Conference: Syndax will present 23 abstracts, including 6 oral presentations, showcasing the efficacy and safety of Revuforj and axatilimab.

3. Forward Guidance and Outlook

• Expectation for accelerated sales growth in Q4 due to the recent NPM1 approval and increasing average duration of therapy for KMT2A patients.
• Anticipated average duration of therapy for KMT2A patients to increase to 6-12 months in 2026 as more patients return post-transplant.
• Confidence in reaching profitability with current cash reserves and ongoing revenue growth from both Revuforj and Niktimvo.

4. Challenges and Points of Concern

• Gross to Net Adjustments: Increased adjustments due to higher 340B business and Medicare/Medicaid exposure, impacting net revenue growth despite strong prescription demand.
• Patient Dynamics: Approximately 1/3 of KMT2A patients are pausing treatment for stem cell transplants, which could affect revenue stability in the short term until more patients return to maintenance therapy.
• Competitive Landscape: Potential competition in the NPM1 space, although Syndax believes its product profile will maintain a dominant position.

5. Notable Q&A Insights

• Revuforj Utilization: The drug is increasingly being used in earlier lines of therapy, with about 70% of usage now in second and third lines, which could lead to better patient outcomes and longer treatment durations.
• Maintenance Therapy: A significant percentage (35-40%) of patients who undergo transplant are expected to resume Revuforj, with physicians expressing a strong inclination to restart therapy.
• Payer Access: No significant pushback from payers has been observed, with formulary coverage for Revuforj at 97% for KMT2A, and expectations for similar coverage for NPM1.
• Safety Profile: The safety profile remains favorable, with low rates of serious adverse events reported, and physicians are comfortable managing the drug's side effects.

This summary encapsulates the key points from Syndax Pharmaceuticals' Q3 2025 earnings call, highlighting both the positive momentum in their business and the challenges they face moving forward.